Company: GURE
Filing Date: 2025-04-11
Form Type: 10-K
Source: 0001193805-25-000461
Chunk: 33

Company: GULF RESOURCES, INC.
Filing Date: 2025-04-11
Form: 10-K
Item: Item 1A
Chunk 33
---
Item 1A. Risk Factors.

Pursuant to Item 301(c) of Regulation
S-K (§ 229.301(c)), the Company is not required to provide the information required by this Item as it is a “smaller reporting
company,” as defined by Rule 229.10(f)(1).

We
are currently not in compliance with the Nasdaq continued listing requirements. If we are unable to regain compliance with Nasdaq’s
listing requirements, our securities could be delisted, which could affect our common stock’s market price and liquidity and reduce
our ability to raise capital.

On
November 5, 2024, the Company received a notice in the form of a letter (“Price Deficiency Letter”) from Nasdaq stating that
the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the bid price for the Company’s common stock had closed
below $1.00 per share for the previous 34 consecutive business days (the “Minimum Bid Price Requirement”). In accordance with
Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until May 5, 2025, to regain compliance with the Minimum
Bid Price Requirement. If at any time before May 5, 2025, the bid price of the Company’s common stock closes at $1.00 per share
or more for a minimum of 10 consecutive business days, the Staff Nasdaq will provide written confirmation that the Company has achieved
compliance. In the event the Company does not regain compliance, the Company may be eligible for additional time. To qualify for the additional
compliance period, the Company will be required to (i) submit, no later than the expiration date, an on-line Transfer Application, (ii)
submit a non-refundable $5,000 application fee, (iii) meet the continued listing requirement for the market value of its publicly held
shares and all other continued listing standards for The Nasdaq Stock Market, with the exception of the bid price requirement, and (iv)
will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse
stock split if necessary. As part of its review process, the Nasdaq will make a determination of whether they believe the Company will
be able to cure this deficiency. Should the Nasdaq conclude that the Company will not be able to cure the deficiency, or should the Company